Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study
- 1 February 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 91, 107038
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Assessing the Complex Causes of Kidney Allograft LossTransplantation, 2020
- Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft RecipientsJournal of the American Society of Nephrology, 2017
- The Histology of Kidney Transplant FailureTransplantation, 2014
- Chronic alloantibody mediated rejectionSeminars in Immunology, 2012
- Recurrent glomerular disease after kidney transplantationCurrent Opinion in Nephrology and Hypertension, 2010
- Recurrent Glomerulonephritis after Renal TransplantationClinical Journal of the American Society of Nephrology, 2008
- Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent EraAmerican Journal of Transplantation, 2004
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant PatientsJournal of the American Society of Nephrology, 2002
- Risk of Renal Allograft Loss from Recurrent GlomerulonephritisNew England Journal of Medicine, 2002